Sarepta and Roche announced a 16-year-old US patient dosed with the gene therapy died of acute liver failure in March 2025.

Sarepta Therapeutics (NASDAQ:SRPT) announced Friday that the company and its partner Roche (OTCQX:RHHBY) expect to provide EU ...

In response to a request from the European Medicines Agency (EMA) following the death of a 16-year-old patient in the U.S., ...

The EMA has called a temporary halt to a phase 2 trial of Sarepta's Roche-partnered Duchenne muscular dystrophy (DMD) gene ...

The Swiss drugmaker, which holds European rights to Elevidys, suspended three trials while researchers investigate the death ...

Roche Holdings AG (OTC:RHHBY) on Thursday presented new data at the AD/PD 2025 International Conference on Alzheimer’s and ...

Sarepta Therapeutics said on Friday it had temporarily halted three trials testing its gene therapy Elevidys, following the death of a patient last month upon receiving the treatment.

Therapeutics shared the following update related to ELEVIDYS, the only approved gene therapy in patients with Duchenne muscular ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved ...

Sarepta Therapeutics (NASDAQ:SRPT) announced Friday that the company and its partner Roche (OTCQX:RHHBY) expect to provide EU officials with data in support of their gene therapy Elevidys ...

Roche, the company to which the treatment is ... HC Wainwright upgraded Sarepta on Wednesday from Sell to Neutral, saying it is trading within a fair range. Analyst Mitchell S.